125050-18-2

Upstream product

• 125076-26-8 2-benzyloxycarbonylamino-5-hydroxy-pentanoic acid tert-butyl ester 
• 5891-45-2 N-benzoyloxycarbonyl D-glutamic acid α-t-benzyl ester 
• 125134-29-4 (R)-5-Oxo-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 
• 1155-62-0 2-Benzyloxycarbonylamino-pentanedioic acid 
• 540-88-5 acetic acid tert-butyl ester 
• 125076-26-8 2-Benzyloxycarbonylamino-5-hydroxy-pentanoic acid tert-butyl ester 

Downstream Products

• 125050-16-0 N-(benzyloxy)amide of α-N-carbobenzoxy-δ-bromo-D-norvaline 

Relevant academic research and scientific papers

ACE-INHIBITORS HAVING ANTIOXIDANT AND NO-DONOR ACTIVITY

Multifonctional ACE inhibitor compounds are provided, that combine ACE-inhibiting activity with capability to scavenge superoxide and other reactive oxygen species, and that may further function as nitric oxide donors. The compounds are useful for preventing or treating various disorders, including cardiovascular, and diabetes associated disorders.

1-Hydroxy-3-amino-2-piperidone (δ-N-Hydroxycycloornithine) Derivatives: Key Intermediates for the Synthesis of Hydroxamate-Based Siderophores

Several routes for the synthesis of δ-N-(benzyloxy)cycloornithine (2) from glutamic acid derived starting materials are described.Efficient methods were developed for the synthesis of glutamic acid γ-semialdehyde and γ-hydroxynorvaline derivatives as key substrates for the preparation of δ-N-hydroxyornithine analogues.Thus, the best approaches to the synthesis of 2 were: (1) reductive cyclization of an N-hydroxysuccinimide ester of the O-benzyloxime 4 of α-amino-protected glutamic acid γ-semialdehyde 5 and (2) cyclization of the N-(benzyloxy)amide of δ-bromonorvaline (7).